GlaxoSmithKline profits up on lower tax

British drugmaker GlaxoSmithKline on Wednesday said its second quarter net profit rose 13.3 percent from a year earlier to £1.25 billion ($1.94 billion, 1.59 billion euros).

GSK's earnings got a lift from lower tax payments, offsetting a 4.0-percent drop in revenues to £6.46 billion in the three months to June.

Sales slid 8.0 percent in Europe and by 6.0 percent in the United States, reflecting a "challenging macro-economic environment, genericisation (of drugs) and discontinuation of certain products," Britain's biggest pharmaceuticals firm said.

"Our performance this quarter reflects the challenging macro-economic environment in which we are operating and the continued transition of our product portfolio," GSK chief executive Andrew Witty said in a results statement.

"Ultimately, the ability of companies in our sector to succeed in this environment and in the future will be determined by how successful they are in accessing growth markets and delivering valuable new product flow on a sustainable basis."

GSK's current quarter has meanwhile started with a bang, clinching the takeover of US research partner Human Genome Sciences Inc. after increasing its bid to $3.0 billion (2.4 billion euros).

At the same time, the company was hit by fines totalling $3.0 billion by US authorities over charges it marketed drugs for unauthorised uses, held back safety data and cheated the government's Medicaid program.

add to favorites email to friend print save as pdf

Related Stories

GlaxoSmithKline says net profits drop 13% in Q1

Apr 25, 2012

British drugsmaker GlaxoSmithKline said Wednesday that its net profits dropped 13 percent to £1.325 billion (1.616 billion euros, $2.134 billion) in the first quarter from a year earlier.

GlaxoSmithKline posts rising Q3 profits

Oct 26, 2011

British drugmaker GlaxoSmithKline said Wednesday that third-quarter net profit rose seven percent, boosted by growth across its main pharmaceuticals, vaccines and consumer healthcare divisions.

Recommended for you

Face transplants change lives, identity

11 hours ago

Patients are prepared to take significant risks in order to be considered for a face transplant, says Dr David Koppel, director of the largest craniofacial unit in the UK and Honorary Clinical Associate Professor ...

British Lords hold ten-hour debate on assisted dying

Jul 19, 2014

Members of Britain's unelected House of Lords spent almost ten hours on Friday discussing whether to legalise assisted dying, in an often emotional debate putting the question back on the agenda, if not on the statute books.

AbbVie, Shire agree on $55B combination

Jul 18, 2014

The drugmaker AbbVie has reached a deal worth roughly $55 billion to combine with British counterpart Shire and become the latest U.S. company to seek an overseas haven from tax rates back home.

User comments